These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38869976)

  • 21. Update on geographic atrophy in age-related macular degeneration.
    Biarnés M; Monés J; Alonso J; Arias L
    Optom Vis Sci; 2011 Jul; 88(7):881-9. PubMed ID: 21532519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside.
    Sachdeva MM; Eliott D
    Semin Ophthalmol; 2016; 31(1-2):25-9. PubMed ID: 26959126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hot Topics in Dry AMD.
    Narayanan R; Kuppermann BD
    Curr Pharm Des; 2017; 23(4):542-546. PubMed ID: 28003009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stem cell based therapies for age-related macular degeneration: The promises and the challenges.
    Nazari H; Zhang L; Zhu D; Chader GJ; Falabella P; Stefanini F; Rowland T; Clegg DO; Kashani AH; Hinton DR; Humayun MS
    Prog Retin Eye Res; 2015 Sep; 48():1-39. PubMed ID: 26113213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dry age-related macular degeneration: recent progress of therapeutic approaches.
    Kuno N; Fujii S
    Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Progression of treatment and researches in dry age related macular degeneration].
    Zhang K; Tang S
    Zhonghua Yan Ke Za Zhi; 2015 Mar; 51(3):236-40. PubMed ID: 26268648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancements in Imaging and Therapeutic Options for Dry Age-Related Macular Degeneration and Geographic Atrophy.
    Servillo A; Sacconi R; Oldoni G; Barlocci E; Tombolini B; Battista M; Fantaguzzi F; Rissotto F; Mularoni C; Parravano M; Zucchiatti I; Querques L; Bandello F; Querques G
    Ophthalmol Ther; 2024 Aug; 13(8):2067-2082. PubMed ID: 38833127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
    Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigational drugs in clinical trials for macular degeneration.
    Tolentino MJ; Tolentino AJ
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on Clinical Trials in Dry Age-related Macular Degeneration.
    Taskintuna I; Elsayed ME; Schatz P
    Middle East Afr J Ophthalmol; 2016; 23(1):13-26. PubMed ID: 26957835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-related macular degeneration (AMD): pathogenesis and therapy.
    Nowak JZ
    Pharmacol Rep; 2006; 58(3):353-63. PubMed ID: 16845209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stem cell-based therapies for age-related macular degeneration: current status and prospects.
    Mu Y; Zhao M; Su G
    Int J Clin Exp Med; 2014; 7(11):3843-52. PubMed ID: 25550892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy for age-related macular degeneration: potential, feasibility, and pitfalls.
    Berkowitz ST; Finn AP
    Curr Opin Ophthalmol; 2024 May; 35(3):170-177. PubMed ID: 38441066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging treatments for geographic atrophy in age-related macular degeneration.
    Mahmoudzadeh R; Hinkle JW; Hsu J; Garg SJ
    Curr Opin Ophthalmol; 2021 May; 32(3):294-300. PubMed ID: 33630787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration.
    Akyol E; Lotery A
    Biologics; 2020; 14():83-94. PubMed ID: 32982165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic options in age-related exudative macular degeneration].
    Stanca HT
    Oftalmologia; 2007; 51(1):7-11. PubMed ID: 17605263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of gene therapies for age-related macular degeneration.
    Khanani AM; Thomas MJ; Aziz AA; Weng CY; Danzig CJ; Yiu G; Kiss S; Waheed NK; Kaiser PK
    Eye (Lond); 2022 Feb; 36(2):303-311. PubMed ID: 35017696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration.
    Fei X; Jung S; Kwon S; Kim J; Corson TW; Seo SY
    Arch Pharm Res; 2024 Jun; 47(6):538-557. PubMed ID: 38902481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Zhou Q; Daniel E; Maguire MG; Grunwald JE; Martin ER; Martin DF; Ying GS;
    Ophthalmology; 2016 Jul; 123(7):1530-40. PubMed ID: 27040149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.